Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory Immunotherapy

Active, not recruiting

• Conditions: Myeloproliferative Neoplasm; Inflammatory Disease

• Registration Number: NCT06476535
• Lead Sponsor: University Hospital, Brest

Brief Summary

The study will collect cases of MPN patients who also benefit from an anti-inflammatory immunotherapy for another disease. Efficacy and tolerability of the drug will be assessed in this population.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-06
• Study Start: 2024-06-11
• Study First Submitted: 2024-06-13
• Study First Submitted QC: 2024-06-25
• Last Update Submitted: 2024-06-25
• Study First Posted: 2024-06-26
• Last Update Posted: 2024-06-26
• Primary Completion: 2026-05-31
• Study Completion: 2026-05-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• MyeloProliferative Neoplasm diagnosis
• receiving or having received an immunotherapy targeting IL-1, IL-6, IL-17, IL-23 or TNF

Exclusion Criteria

• Unable to consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficacy of the anti-inflammatory immunotherapy	1 year	Depending on the indication of the anti-inflammatory treatment, clinical efficacy will be assessed clinically as number of patients reaching complete (total disappearance of initial symptoms- diarrhea, arthritis, fever, skin lesions), partial (improvement of symptoms, but not total disappearance) or absence of response (the treatment did not improve the symptoms). Clinical judgement will be according to the physician appreciation.
Tolerability of the anti-inflammatory immunotherapy	1 year	Tolerability will be assessed as the number of reported unexpected side effects attributed to the treatment as judged by the caring physician, including treatment discontinuation

Trial Locations

Locations (1)

Chu Brest; 🇫🇷 Brest, France